Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].

Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE.

Leuk Res. 2017 Aug;59:65. doi: 10.1016/j.leukres.2017.02.007. Epub 2017 May 30. No abstract available.

PMID:
28575698
2.

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.

Charmsaz S, Al-Ejeh F, Yeadon TM, Miller KJ, Smith FM, Stringer BW, Moore AS, Lee FT, Cooper LT, Stylianou C, Yarranton GT, Woronicz J, Scott AM, Lackmann M, Boyd AW.

Leukemia. 2017 Aug;31(8):1779-1787. doi: 10.1038/leu.2016.371. Epub 2016 Dec 6.

PMID:
27922598
3.

KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.

Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE.

Leuk Res. 2016 Nov;50:123-131. doi: 10.1016/j.leukres.2016.09.012. Epub 2016 Sep 28. Erratum in: Leuk Res. 2017 Aug;59:65.

PMID:
27736729
4.

CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.

Pan C, Cardarelli PM, Nieder MH, Pickford LB, Gangwar S, King DJ, Yarranton GT, Buckman D, Roscoe W, Zhou F, Salles A, Chen TH, Horgan K, Wang YH, Nguyen T, Bebbington CR.

Cancer Res. 2003 Sep 1;63(17):5526-31.

5.

Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study.

Casey JL, Napier MP, King DJ, Pedley RB, Chaplin LC, Weir N, Skelton L, Green AJ, Hope-Stone LD, Yarranton GT, Begent RH.

Br J Cancer. 2002 May 6;86(9):1401-10.

6.

CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

Dubois V, Dasnois L, Lebtahi K, Collot F, Heylen N, Havaux N, Fernandez AM, Lobl TJ, Oliyai C, Nieder M, Shochat D, Yarranton GT, Trouet A.

Cancer Res. 2002 Apr 15;62(8):2327-31.

7.

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.

Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RH.

Br J Cancer. 1999 Nov;81(6):972-80.

8.

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.

Casey JL, King DJ, Chaplin LC, Haines AM, Pedley RB, Mountain A, Yarranton GT, Begent RH.

Br J Cancer. 1996 Nov;74(9):1397-405.

9.

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).

Antoniw P, Farnsworth AP, Turner A, Haines AM, Mountain A, Mackintosh J, Shochat D, Humm J, Welt S, Old LJ, Yarranton GT, King DJ.

Br J Cancer. 1996 Aug;74(4):513-24.

10.

The secretion of active recombinant human gastric lipase by Saccharomyces cerevisiae.

Crabbe T, Weir AN, Walton EF, Brown ME, Sutton CW, Tretout N, Bonnerjea J, Lowe PA, Yarranton GT.

Protein Expr Purif. 1996 May;7(3):229-36.

PMID:
8860647
11.

Expression, purification and characterization of B72.3 Fv fragments.

King DJ, Byron OD, Mountain A, Weir N, Harvey A, Lawson AD, Proudfoot KA, Baldock D, Harding SE, Yarranton GT, et al.

Biochem J. 1993 Mar 15;290 ( Pt 3):723-9.

12.

Inducible vectors for expression in mammalian cells.

Yarranton GT.

Curr Opin Biotechnol. 1992 Oct;3(5):506-11. Review.

PMID:
1368935
13.

High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker.

Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT.

Biotechnology (N Y). 1992 Feb;10(2):169-75.

PMID:
1369477
14.

Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment.

King DJ, Adair JR, Angal S, Low DC, Proudfoot KA, Lloyd JC, Bodmer MW, Yarranton GT.

Biochem J. 1992 Jan 15;281 ( Pt 2):317-23.

15.

The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines.

Cockett MI, Bebbington CR, Yarranton GT.

Nucleic Acids Res. 1991 Jan 25;19(2):319-25.

16.

Mammalian recombinant proteins: vectors and expression systems.

Yarranton GT.

Curr Opin Biotechnol. 1990 Dec;1(2):133-40. Review. No abstract available.

PMID:
1367850
17.

Site-specific attachment to recombinant antibodies via introduced surface cysteine residues.

Lyons A, King DJ, Owens RJ, Yarranton GT, Millican A, Whittle NR, Adair JR.

Protein Eng. 1990 Aug;3(8):703-8.

PMID:
2120698
19.
20.

A chink in HIV's armour?

Stephens PE, Clements G, Yarranton GT, Moore J.

Nature. 1990 Jan 18;343(6255):219. No abstract available.

PMID:
2300166
21.

Recovery of recombinant proteins from yeast.

King DJ, Walton F, Smith BW, Dunn M, Yarranton GT.

Biochem Soc Trans. 1988 Dec;16(6):1083-6. No abstract available.

PMID:
3066664
22.

Molecular cloning of a human gastric lipase and expression of the enzyme in yeast.

Bodmer MW, Angal S, Yarranton GT, Harris TJ, Lyons A, King DJ, Pieroni G, Riviere C, Verger R, Lowe PA.

Biochim Biophys Acta. 1987 Aug 25;909(3):237-44.

PMID:
3304425
23.
24.

Investigation of the instability of plasmids directing the expression of Met-prochymosin in Escherichia coli.

Caulcott CA, Lilley G, Wright EM, Robinson MK, Yarranton GT.

J Gen Microbiol. 1985 Dec;131(12):3355-65.

PMID:
3938475
25.

Dual-origin plasmid vectors whose origin of replication is controlled by the coliphage lambda promoter pL.

Yarranton GT, Wright E, Robinson MK, Humphreys GO.

Gene. 1984 Jun;28(3):293-300.

PMID:
6204909
26.

How cells in distress use SOS.

Sedgwick SG, Yarranton GT.

Nature. 1982 Apr 15;296(5858):606-7. No abstract available.

PMID:
7070507
27.
28.

Inducible DNA repair in Ustilago maydis.

Lee MG, Yarranton GT.

Mol Gen Genet. 1982;185(2):245-50.

PMID:
6953306
29.
30.

Detection of the catalytic activities of DNA polymerases and their associated exonucleases following SDS-polyacrylamide gel electrophoresis.

Spanos A, Sedgwick SG, Yarranton GT, Hübscher U, Banks GR.

Nucleic Acids Res. 1981 Apr 24;9(8):1825-39.

31.

Lysogenic induction of lambdoid phages in lexA mutants of Escherichia coli.

Sedgwick SG, Yarranton GT, Heath RW.

Mol Gen Genet. 1981;184(3):457-9.

PMID:
6460916
32.

Enzyme-catalyzed DNA unwinding. The role of ATP in helicase III activity.

Das RH, Yarranton GT, Gefter ML.

J Biol Chem. 1980 Sep 10;255(17):8069-73.

33.

Enzyme-catalyzed DNA unwinding. Mechanism of action of helicase III.

Yarranton GT, Das RH, Gefter ML.

J Biol Chem. 1979 Dec 10;254(23):12002-6. No abstract available.

34.

Enzyme-catalyzed DNA unwinding. A DNA-dependent ATPase from E. coli.

Yarranton GT, Das RH, Gefter ML.

J Biol Chem. 1979 Dec 10;254(23):11997-2001.

35.

Enzyme-catalyzed DNA unwinding: studies on Escherichia coli rep protein.

Yarranton GT, Gefter ML.

Proc Natl Acad Sci U S A. 1979 Apr;76(4):1658-62.

38.
39.

A DNA polymerase from Ustilago maydis. 1. Purification and properties of the polymerase activity.

Banks GR, Holloman WK, Kairis MV, Spanos A, Yarranton GT.

Eur J Biochem. 1976 Feb 2;62(1):131-42.

Supplemental Content

Loading ...
Support Center